Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Payables (2016 - 2025)

Historic Payables for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $1.7 million.

  • Seres Therapeutics' Payables fell 7968.26% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 7968.26%. This contributed to the annual value of $4.1 million for FY2024, which is 1202.97% up from last year.
  • Per Seres Therapeutics' latest filing, its Payables stood at $1.7 million for Q3 2025, which was down 7968.26% from $2.2 million recorded in Q2 2025.
  • Seres Therapeutics' Payables' 5-year high stood at $18.0 million during Q3 2021, with a 5-year trough of $1.7 million in Q3 2025.
  • Moreover, its 5-year median value for Payables was $8.3 million (2024), whereas its average is $8.8 million.
  • In the last 5 years, Seres Therapeutics' Payables skyrocketed by 20713.33% in 2021 and then crashed by 7968.26% in 2025.
  • Seres Therapeutics' Payables (Quarter) stood at $13.7 million in 2021, then skyrocketed by 30.29% to $17.9 million in 2022, then tumbled by 79.65% to $3.6 million in 2023, then grew by 12.03% to $4.1 million in 2024, then tumbled by 58.89% to $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q3 2025, $2.2 million for Q2 2025, and $2.2 million during Q1 2025.